Skip to main content
U.S. flag

An official website of the United States government

This site is currently in beta, and your feedback is helping shape its ongoing development.

Elosulfase alfa

Published by U.S. Food and Drug Administration | U.S. Department of Health & Human Services | Metadata Last Checked: February 18, 2026 | Last Modified: 2025-03-17
VIMIZIM (elosulfase alfa) is an injectable enzyme replacement therapy used to treat Mucopolysaccharidosis Type IVA (Morquio A syndrome), a rare genetic disorder. It works by providing the missing enzyme to break down certain sugars in the body. Administered intravenously by a healthcare professional, it's available as a 5 mg/5 mL solution. Manufactured by BioMarin Pharmaceutical Inc. This information was generated using AI and is provided for informational and research purposes only.

Find Related Datasets

Click any tag below to search for similar datasets

data.gov

An official website of the GSA's Technology Transformation Services

Looking for U.S. government information and services?
Visit USA.gov